123 related articles for article (PubMed ID: 9744315)
1. Prognostic significance of stromelysin 3, gelatinase A, and urokinase expression in breast cancer.
Têtu B; Brisson J; Lapointe H; Bernard P
Hum Pathol; 1998 Sep; 29(9):979-85. PubMed ID: 9744315
[TBL] [Abstract][Full Text] [Related]
2. Expression of cathepsin D, stromelysin-3, and urokinase by reactive stromal cells on breast carcinoma prognosis.
Têtu B; Brisson J; Wang CS; Lapointe H; Beaudry G; Blanchette C
Cancer; 2001 Dec; 92(11):2957-64. PubMed ID: 11753972
[TBL] [Abstract][Full Text] [Related]
3. Stromelysin 3: an independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression.
Ahmad A; Hanby A; Dublin E; Poulsom R; Smith P; Barnes D; Rubens R; Anglard P; Hart I
Am J Pathol; 1998 Mar; 152(3):721-8. PubMed ID: 9502414
[TBL] [Abstract][Full Text] [Related]
4. Cathepsin D expression by cancer and stromal cells in breast cancer: an immunohistochemical study of 1348 cases.
Têtu B; Brisson J; Lapointe H; Wang CS; Bernard P; Blanchette C
Breast Cancer Res Treat; 1999 May; 55(2):137-47. PubMed ID: 10481941
[TBL] [Abstract][Full Text] [Related]
5. Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations.
Pacheco MM; Mourão M; Mantovani EB; Nishimoto IN; Brentani MM
Clin Exp Metastasis; 1998 Oct; 16(7):577-85. PubMed ID: 9932604
[TBL] [Abstract][Full Text] [Related]
6. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
[TBL] [Abstract][Full Text] [Related]
7. S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer.
Malmström P; Bendahl PO; Boiesen P; Brünner N; Idvall I; Fernö M;
J Clin Oncol; 2001 Apr; 19(7):2010-9. PubMed ID: 11283134
[TBL] [Abstract][Full Text] [Related]
8. [Expression and significance of urokinase-type plasminogen activator in breast cancer].
Xiao J; Zhang G; Xia W
Zhonghua Zhong Liu Za Zhi; 1999 May; 21(3):196-8. PubMed ID: 11776834
[TBL] [Abstract][Full Text] [Related]
9. Correlation between stromelysin-3 mRNA level and outcome of human breast cancer.
Engel G; Heselmeyer K; Auer G; Bäckdahl M; Eriksson E; Linder S
Int J Cancer; 1994 Sep; 58(6):830-5. PubMed ID: 7927875
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study.
Broët P; Spyratos F; Romain S; Quillien V; Daver A; Ricolleau G; Rallet A; Toulas C; Asselain B
Br J Cancer; 1999 May; 80(3-4):536-45. PubMed ID: 10408864
[TBL] [Abstract][Full Text] [Related]
11. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
Buta M; Džodić R; Đurišić I; Marković I; Vujasinović T; Markićević M; Nikolić-Vukosavljević D
Tumour Biol; 2015 Sep; 36(10):8193-200. PubMed ID: 25994573
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer.
Leissner P; Verjat T; Bachelot T; Paye M; Krause A; Puisieux A; Mougin B
BMC Cancer; 2006 Aug; 6():216. PubMed ID: 16945123
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
Grøndahl-Hansen J; Christensen IJ; Briand P; Pappot H; Mouridsen HT; Blichert-Toft M; Danø K; Brünner N
Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.
Peyrat JP; Vanlemmens L; Fournier J; Huet G; Révillion F; Bonneterre J
Clin Cancer Res; 1998 Jan; 4(1):189-96. PubMed ID: 9516970
[TBL] [Abstract][Full Text] [Related]
15. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
Look MP; van Putten WL; Duffy MJ; Harbeck N; Christensen IJ; Thomssen C; Kates R; Spyratos F; Fernö M; Eppenberger-Castori S; Sweep CG; Ulm K; Peyrat JP; Martin PM; Magdelenat H; Brünner N; Duggan C; Lisboa BW; Bendahl PO; Quillien V; Daver A; Ricolleau G; Meijer-van Gelder ME; Manders P; Fiets WE; Blankenstein MA; Broët P; Romain S; Daxenbichler G; Windbichler G; Cufer T; Borstnar S; Kueng W; Beex LV; Klijn JG; O'Higgins N; Eppenberger U; Jänicke F; Schmitt M; Foekens JA
J Natl Cancer Inst; 2002 Jan; 94(2):116-28. PubMed ID: 11792750
[TBL] [Abstract][Full Text] [Related]
16. Markers of progression and invasion in short term follow up of untreated breast cancer patients.
Rabi ZA; Todorović-Raković N; Vujasinović T; Milovanović J; Nikolić-Vukosavljević D
Cancer Biomark; 2015; 15(6):745-54. PubMed ID: 26406416
[TBL] [Abstract][Full Text] [Related]
17. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
Schmitt M; Jänicke F; Graeff H
Blood Coagul Fibrinolysis; 1990 Dec; 1(6):695-702. PubMed ID: 2133250
[TBL] [Abstract][Full Text] [Related]
18. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
[TBL] [Abstract][Full Text] [Related]
19. Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.
Duffy MJ; Maguire TM; McDermott EW; O'Higgins N
J Surg Oncol; 1999 Jun; 71(2):130-5. PubMed ID: 10389872
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
